has received approval from Japan鈥檚 Ministry of Health, Labour and Welfare for its therapy Abecma (idecabtagene vicleucel) to treat relapsed or refractory (R/R) multiple myeloma in adults, according to an .
Abecma is a chimeric antigen receptor (CAR) T cell immunotherapy directed by B-cell maturation antigen (BCMA).
In March last year, the company鈥檚 CD19-directed genetically modified autologous T cell immunotherapy Breyanzi received approval.
With the latest approval, now has two approved CAR T cell therapies.
The Ministry鈥檚 approval is based on safety and efficacy data obtained from the international Phase II Study BB2121-MM-001 and the Phase I Study CRB-401 conducted in the US.
The Phase II study was conducted in Japan, the EU, the US and Canada.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBristol-Myers Squibb president and CEO Jean-Christophe Barland said: 鈥淎becma delivers a new treatment option for patients with multiple myeloma, the first option directed against BCMA and using a new mode of action.
鈥淭his approval is a testament to our strong commitment to addressing unmet medical needs for patients in Japan. As a game-changer committed to ‘innovation with heart,’ Bristol Myers Squibb Japan will continue its efforts to help patients prevail over serious diseases.鈥�
The personalised immune cell therapy Abecma, which received approval as a one-time infusion, identifies and attaches to the BCMA protein as an anti-BCMA CAR T cell therapy.
BCMA is universally expressed on multiple myeloma cancer cells and results in their death.
Till now, multiple myeloma has no approved therapeutic options in Japan.
Last August, the European Commission granted conditional marketing authorisation to Bristol Myers Squibb鈥檚 Abecma to treat relapsed and refractory multiple myeloma in adult patients.
Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
